Pandemic-era NIH grants (FY2019-2024) covering coronavirus, gain-of-function research, mRNA vaccines, biosafety, and related funding flows. Metadata + abstracts from NIH RePORTER.
Get an AI answer drawn only from the NIH Pandemic-Era Grants documents indexed here — every claim cited back to the filing or proceeding it came from. It will tell you plainly when the record doesn't cover your question, rather than guessing.
Heinrich Feldmann · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2024 · $182,814 — Emerging/re-emerging zoonotic diseases are a major global health problem. Linking comprehensive pathogen surveillance of arthropod/vector populations in Uganda with public health surveillance at the regional and international level will make an important contribution to human and animal health in Ea…
Mario Roederer · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2024 · $17,731 — Structure-based design and protein engineering principles were applied to stabilize the fusion (F) protein in its prefusion trimeric conformation (pre-F) to improve expression and increase immunogenicity. We covalently linked the stabilized pre-F through trimerization domains at the C-terminus to th…
Purveshkumar Khatri · STANFORD UNIVERSITY · 2024 · $334,498 — ABSTRACT – Data Management and Analysis Core. Identifying the biological features of the human immune response that correlate with and predict the development of an effective immune response to vaccination is an overarching goal of this U19 consortium. The Data Management and Analysis Core (DMAC) in…
Andrea Goldberg Edlow · MASSACHUSETTS INSTITUTE OF TECHNOLOGY · 2024 · $669,960 — Project 1: Summary The COVID-19 pandemic has revolutionized our ability to decode the rules of maternal immunity. There is a significant gap in knowledge regarding innate and adaptive immune responses over the course of pregnancy and how trimester-specific perturbations in the maternal immunological…
Kristina De Paris · UNIV OF NORTH CAROLINA CHAPEL HILL · 2024 · $240,080 — ABSTRACT – B Cell Core Early development of bNAbs in infants suggest potentially distinct mechanisms in the generation of antibody breadth due to the highly dynamic nature of the infant immune system. Moreover, we have observed elicitation of bNAb precursors in infant rhesus monkeys with germline-ta…
Patrick Kellish · UNIVERSITY OF FLORIDA · 2024 · $78,287 — FLOW CYTOMETRY AND CONFOCAL MICROSCOPY SHARED RESOURCE (CYT-SR): ABSTRACT CYT-SR provides University of Florida Health Cancer Center (UFHCC) members with cost-effective, state-of- the-art flow cytometry and modern confocal microscopy expertise, instrumentation, and services to support their research…
Leonidas Stamatatos · FRED HUTCHINSON CANCER CENTER · 2024 · $1,393,751 — Abstract: The goals of Scientific Project Two are the manufacturing and release of two cGMP saRNA/NLC HIV-1 Env-derived vaccine candidates and the establishment of an ICH-compliant stability program for these vaccines. The two vaccines consist of a self-amplifying RNA (saRNA) encoding two HIV-1 Env…
Viviana A Simon · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · 2024 · $272,530 — SUMMARY The VIVA Clinical Core B provides the infrastructures needs to support standardized approaches for the recruitment, longitudinal retention and clinical characterization of human subjects enrolled in observational studies. The Core B will facilitate patient centered research through activitie…
Frederic D Bushman · UNIVERSITY OF PENNSYLVANIA · 2024 · $172,353 — SUMMARY- CORE B (GENOMICS CORE) Core B (Genomics Core) will provide key support to the mVACS team in Clostridioides difficile genome sequence analysis, antigen design, microbiome sequence analysis, routine statistical analysis, and high content data management. Core B will use advanced genomics-base…
Brendan Joseph Kelly · UNIVERSITY OF PENNSYLVANIA · 2024 · $215,035 — SUMMARY – CORE C (CLINICAL CORE) Core C (Clinical Core) will support the overall mVACS program goal to develop modified mRNA vaccines to eliminate C.difficile infection (CDI) by developing an infrastructure for CDI human subject identification, specimen biobanking, and metadata collection to study t…
Kristina De Paris · WEILL MEDICAL COLL OF CORNELL UNIV · 2024 · $668,200 — ABSTRACT – Project 2 Globally, about 600,000 young adults (15-24 years of age) became infected with HIV-1 in 2017. Young women age 15-19 years are most affected, and HIV-infection in this age group continue to rise. Therefore, a vaccine to prevent HIV acquisition in young adults remains a top priori…
Adolfo Garcia-Sastre · ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI · 2024 · $403,954 — Two years into the COVID-19 pandemic, SARS-CoV-2 infections are still responsible for huge economic losses, lockdowns and stressed health care systems worldwide. Different from the situation early during the pandemic, when the virus started circulating in the human population in the absence of pre-e…
Richard Thomas Wyatt · SCRIPPS RESEARCH INSTITUTE, THE · 2024 · $674,912 — Summary Circulating (tier 2) HIV-1 variants are highly resistant to antibody-mediated neutralization, making broadly effective vaccine design a major challenge. Encouragingly, work in our previous HIVRAD program demonstrated that Ab responses capable of cross-neutralizing multiple heterologous ti…
Barton F. Haynes · DUKE UNIVERSITY · 2024 · $1,035,959 — Vaccine trials in non-human primates challenged with R5, tier 2 SHIVs have shown protection in the presence of high levels of non-neutralizing antibodies (NNAbs), and one of the 5 Phase IIb HIV-1 vaccine efficacy trials using alum (ALVAC/AIDSVAX in RV144) showed an estimated vaccine efficacy of 31%,…
Thomas Denny · DUKE UNIVERSITY · 2024 · $5,033,198 — HIV vaccine candidates entering into clinical testing generally fall into three categories: 1) recombinant envelope (Env) protein immunogens, 2) viral vectors, and 3) plasmid DNA. Numerous vaccine Env designs are being tested in clinical trials. Likewise, numerous HIV vaccine inserts, such as mosaic…
Philip Murphy · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2020 · $11,205 — We have written an Animal Study Proposal that has been approved by the NIAID Animal Care and Use Committee. We have not yet begun research because the BSL3 and ABSL3 facilities were not open until summer 2020. We are awaiting approval of our proposal by the BSL3 review committee. In the 1st Year,…
Yasmine Belkaid · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2020 · $3,460,631 — In response to the SARS-CoV-2 pandemic we have made the technologies and platforms at CHI available for characterization of COVID-19 patient samples, as a priority ahead of our ongoing collaborative studies. By early April we had completed adaptation of our transcriptomic and flow cytometry platfor…
Bernard Lafont · NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES · 2020 · $947,283 — Viruses of the Coronaviridae family are enveloped viruses that possess a large (30kb), single-stranded, positive sense, RNA genome that infect a large number of mammals (alpha and beta coronaviruses) and birds (gamma coronaviruses). Four different seasonal coronaviruses (two alpha coronaviruses, 229…
OFER LEVY · BOSTON CHILDREN'S HOSPITAL · 2020 · $184,957 — PROJECT SUMMARY: From a cluster of respiratory illnesses in Wuhan, China, to a worldwide pandemic, the world has learned of a novel coronavirus (SARS-CoV-2) but little is known about the pathogenesis that leads to the disease termed “COVID”. Patients with SARS-CoV-2 infection range from asymptomatic…
Nirav Rati Bhakta · UNIVERSITY OF CALIFORNIA, SAN FRANCISCO · 2020 · $1,405,090 — PROJECT SUMMARY/ABSTRACT COVID-19, the pandemic illness caused by the novel virus SARS-CoV-2, is a serious respiratory illness that has high infectivity and a mortality rate that varies from <1% to up to 20% depending on underlying risk factors. Indeed, disease severity varies markedly based on reco…